Truist Securities Maintains Buy on HCA Healthcare, Raises Price Target to $345
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Macdonald has reaffirmed a Buy rating on HCA Healthcare (NYSE:HCA) and increased the price target from $320 to $345.
January 31, 2024 | 7:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst David Macdonald maintains a Buy rating on HCA Healthcare and raises the price target from $320 to $345, indicating a positive outlook on the stock.
The increase in price target by Truist Securities suggests a strong confidence in HCA Healthcare's future performance. This endorsement from a reputable analyst is likely to instill investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100